Skip to main content

Plus Therapeutics Value Stock - Dividend - Research Selection

Cytori therapeutics

ISIN: US72941H4002 , WKN: A2PPX6

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company\'s second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Plus Therapeutics CEO’s Insightful Presentation Now Available

2024-03-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

2024-03-11
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation

Plus Therapeutics completes dosing in Cohort 5 of ReSPECT-LM Phase 1 trial

2024-03-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript

2024-03-07
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations were $-0.78. PSTV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen. Welcome […]

Plus Therapeutics Is Worried About This – Should You Be Worried Too?

2024-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Plus Therapeutics Full Year 2023 Earnings: Beats Expectations

2024-03-07
Plus Therapeutics ( NASDAQ:PSTV ) Full Year 2023 Results Key Financial Results Revenue: US$4.91m (up by US$4.69m from...

Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials

2024-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Q4 2023 Plus Therapeutics Inc Earnings Call

2024-03-06
Q4 2023 Plus Therapeutics Inc Earnings Call

Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

2024-03-05
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

2024-03-05
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites Current financial forecast for sufficient runway to fund operations into 2H 2025 Management to Host Conference Call March 5, 2024 at 5:00 p.m. ET AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “